Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint

Correction Updates a Reference Link; No Other Content in the Original Release Has Changed

WILMINGTON, Del. and SACRAMENTO, Calif., Sept. 4, 2026 /PRNewswire/ -- Lunai Bioworks, Inc. (NASDAQ: LNAI) ("Lunai" or the "Company") today issued this correction to the press release the Company distributed on August 27, 2026 under the headline "Lunai Bioworks (NASDAQ: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit." The sole correction is to the hyperlink identifying where a copy of the Company's Second Amended Complaint can be found. No other statement in the original release has changed, and the Company is not disclosing any new information in this correction.

A copy of the Second Amended Complaint, filed in the U.S. District Court for the District of Delaware (Civil Action No. 26-549-CFC), is available on the Investor Relations section of the Company's website at https://s201.q4cdn.com/863337820/files/doc_news/2026/Aug/27/attachments/Complaint-SecondAmendedRedacted-ECF037-082826-C.pdf or directly through the court's public docket.

All other statements in the original release, issued August 27, 2026, remain accurate and unchanged.

About Lunai Bioworks

Lunai Bioworks, Inc. (NASDAQ: LNAI) is a biology-first drug discovery company decoding the molecular underpinnings of central nervous system disease. Its Augusta AI platform begins with real human patient data, not cell lines or chemistry, to identify disease sub-populations, trace altered genes to candidate compounds, and validate drug candidates in vivo using CRISPR-induced zebrafish models and proprietary machine vision. Lunai's pipeline targets Alzheimer's disease, Parkinson's disease, epilepsy, and alcohol use disorder. Through its BioSymetrics platform, Lunai also operates an AI-powered biodefense program applying its drug discovery platform in reverse to identify chemical threats and develop countermeasures. Lunai Bioworks was formed through the April 2025 merger of Renovaro Inc. and BioSymetrics, Inc. and is headquartered in California. For more information, visit www.biosymetrics.com.

Forward-Looking Statements

This release contains forward-looking statements, including statements regarding pending litigation, within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations and involve risks and uncertainties, including those related to the outcome of litigation, that could cause actual results to differ materially. Lunai undertakes no obligation to update these statements except as required by law.

SOURCE Lunai Bioworks Inc.